Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Kazia Therapeutics lands key manufacturing patents for paxalisib in US and India

% of readers think this story is Fact. Add your two cents.


Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has secured manufacturing patents for its paxalisib cancer treatment candidate in key territories, extending its patent protection out until 2036.

The oncology-focused drug development company has been awarded manufacturing patents in the US and India, while a similar patent has progressed in Australia and is on track to be granted in the coming quarter.

Further patents remain pending in the European Union, China, Canada and other strategic territories. These are expected to be approved in due course.

“Exceptionally robust protection”

Kazia CEO Dr James Garner said: “As we move towards commercialisation, we have worked closely with our intellectual property counsel to ensure we achieve the maximum possible degree and duration of protection for the intellectual property embodied in paxalisib.

“The original patents for paxalisib protect its chemical structure and have been granted in almost all relevant territories.

“The new suite of patents additionally covers the process by which paxalisib is manufactured and, together with the original composition of matter patents, provide exceptionally robust protection.

“The manufacturing patents are now granted in the US and India, and are also expected to be granted in other key territories after review by the respective patent agencies.”

Shares have been as much as 3.5% higher to A$1.345 while the company’s market cap pre-open was approximately A$172.3 million.

New patents

Crucially, these newly granted manufacturing patents, which expire in 2036, provide an additional layer of protection by covering the process by which paxalisib is manufactured.

According to Kazia, any generic competitor would now need to develop an alternative method of chemical synthesis, which is technically challenging and hence a costly exercise.

Interestingly, existing ‘composition of matter’ patents for the chemical structure of paxalisib generally expire in 2031 but are likely to be eligible for a five-year patent term extension in key territories.

GBM AGILE and paxalisib trials

While it continues to acquire patents in key markets, Kazia is focused on conducting studies with paxalisib, particularly against glioblastoma — the most common and aggressive form of primary brain cancer in adults.

GBM AGILE, a pivotal glioblastoma study for paxalisib’s registration, is currently underway in the United States. The trial is expected to open in Europe during 2021’s second half.

Meanwhile, eight additional studies are active in various forms of brain cancer at leading research hospitals across the US.

Current studies evaluating paxalisib in brain cancer.

These studies are designed and largely funded by the institutions that run them, with input and support from Kazia.

Potentially, the data they generate may provide a path to substantially expand the commercial use of paxalisib.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/953188/kazia-therapeutics-lands-key-manufacturing-patents-for-paxalisib-in-us-and-india-953188.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.